CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Dec. 31, 2020		Dec. 31, 2019
Current Assets
Cash, including cash equivalents of $51.0 and $50.9		$ 364.9		$ 650.6
Restricted cash		7.8		2.9
Accounts receivable (less allowances of $51.1 and $66.6)		259.1		280.2
Receivables from affiliates of Natura &Co		6.1		0.0
Inventories		459.1		452.3
Prepaid expenses and other		204.2		252.1
Held for sale assets		13.9		22.6
Total current assets		1,315.1		1,660.7
Property, plant and equipment, at cost
Land		20.8		20.6
Buildings and improvements		447.1		459.2
Equipment		680.6		641.7
Property, plant and equipment, at cost		1,148.5		1,121.5
Less accumulated depreciation		(709.9)		(633.5)
Property, plant and equipment, net		438.6		488.0
Right-of-use assets		153.1		175.4
Goodwill		83.2		86.2
Deferred tax asset		135.8		161.2
Other assets		438.5		514.8
Total assets		2,564.3		3,086.3
Liabilities
Debt maturing within one year		28.0		1.8
Loans from affiliates of Natura &Co		1,008.6		0.0
Accounts payable		709.4		723.3
Dividends payable		0.0		8.7
Accrued compensation		89.4		114.5
Other accrued liabilities		334.7		410.7
Sales and taxes other than income		89.9		118.7
Income taxes		5.4		7.4
Total current liabilities		2,294.8		1,401.1
Long-term debt		675.4		1,590.4
Long-term operating lease liability		120.9		143.3
Employee benefit plans		133.3		137.6
Long-term income taxes		101.1		128.7
Other liabilities		106.0		90.5
Total liabilities		3,431.5		3,491.6
Leases and Commitments and contingencies (Notes 15 and 18)
Series C convertible preferred stock	[1]	0.0		578.5
Shareholders’ Deficit
Common stock, par value $0.01 - authorized 1,000 shares; issued 101.34 (2019: par value $0.25 - authorized 1,500 shares; issued 770 shares)	[2]	0.0		192.6
Additional paid-in capital		622.8		2,321.2
Retained earnings		(360.5)		2,138.9
Accumulated other comprehensive loss		(1,133.8)		(1,040.0)
Treasury stock, at cost (0 and 319.9 shares)	[1],[2]	0.0		(4,603.3)
Total Avon shareholders’ deficit		(871.5)		(990.6)
Noncontrolling interests		4.3		6.8
Total shareholders’ deficit		(867.2)	[3]	(983.8)
Total liabilities, series C convertible preferred stock and shareholders’ deficit		2,564.3		3,086.3
Discontinued Operations
Liabilities
Current liabilities of discontinued operations and liabilities held for sale		27.1		16.0
Held-for-sale
Liabilities
Current liabilities of discontinued operations and liabilities held for sale		$ 2.3		$ 0.0

[1] On December 30, 2019, an affiliate of Cerberus Capital Management, L.P. ("Cerberus") elected to convert 435,000 shares of Series C Preferred Stock into 87,000,000 shares of the Company’s common stock, par value U.S.$0.25 per share, conditioned on the Conversion Condition (as defined below). See Note 17, Series C Convertible Preferred Stock.

[2] In January 2020, subsequent to the Transaction, the Company restated its certificate of incorporation to effect a change in capitalization of the Company by changing the number of authorized shares of stock from 1,525,000,000 shares (of which (i) 1,500,000,000 shares, par value $0.25 per share, were common stock and (ii) 25,000,000 shares, par value $1.00 per share, were preferred stock) to 1,000 shares of common stock, par value $0.01 per share. As a result of the Merger, all of the issued and outstanding common stock of the Company, being 550,890,788, were canceled and converted. See Note 21, Mergers     with Natura Cosméticos S.A.,.

[3] The number of shares of Common Stock (par value $0.01 per share) outstanding at December 31, 2020 was 101.34.